We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $4 · 1 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
LSTA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
LSTA Earning Date, Earning Analysis and Earning Prediction Intellectia AI
Lisata Therapeutics agrees to $5 per share acquisition by Kuva Labs - Investing.com
Lisata Therapeutics agrees to $5 per share acquisition by Kuva Labs Investing.com
Lisata Therapeutics (LSTA) Files 8-K on Proposed Acquisition and Tender Offer – Key Information for NASDAQ Investors - Minichart
Lisata Therapeutics (LSTA) Files 8-K on Proposed Acquisition and Tender Offer – Key Information for NASDAQ Investors Minichart
Kuva to seek Lisata tender offer (LSTA) under March 6, 2026 merger - Stock Titan
Kuva to seek Lisata tender offer (LSTA) under March 6, 2026 merger Stock Titan
Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing - Investing.com
Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing Investing.com
Tender offer for Lisata Therapeutics (LSTA) delayed as Kuva Labs reevaluates timing - Stock Titan
Tender offer for Lisata Therapeutics (LSTA) delayed as Kuva Labs reevaluates timing Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | — | — | — | — | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.55 | — | — | $0 | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-1.85 | — | — | $0 | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-1.26 | — | — | $0 | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 16. | HC Wainwright & Co. | — | Downgrade | Buy → Neutral | — | HC Wainwright & Co.: Buy → Neutral |
| 2026. 01. 22. | Brookline Capital | — | Downgrade | Buy → Hold | — | Brookline Capital: Buy → Hold |
| 2025. 08. 21. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 07. 16. | Brookline Capital | — | Maintain | Buy → Buy | — | Brookline Capital: Buy |
| 2024. 12. 11. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2024. 11. 21. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.